NEW YORK, NY / ACCESSWIRE / March 24, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?prid=25145&wire=1
Lead Plaintiff Deadline: April 11, 2022
Class Period: May 28, 2021 - November 26, 2021
Allegations against FENC include that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Cabaletta Bio, Inc. (NASDAQ:CABA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=25145&wire=1
Lead Plaintiff Deadline: April 29, 2022
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Allegations against CABA include that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Rivian Automotive, Inc. (NASDAQ:RIVN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/rivian-automotive-inc-loss-submission-form?prid=25145&wire=1
Lead Plaintiff Deadline: May 6, 2022
This lawsuit is on behalf of investors that purchased or otherwise acquired Rivian common stock pursuant and/or traceable to Rivian's initial public offering on November 10, 2021.
Documents issued in connection with the initial public offering contained representations that were materially inaccurate, misleading, and/or incomplete because they failed to disclose, among other things, that the R1T electric pickup truck and R1S electric SUV were underpriced to such a degree that Rivian would have to raise prices shortly after the IPO and that these price increases would tarnish Rivian's reputation as a trustworthy and transparent company and would put a significant number of the existing backlog of 55,400 preorders, along with future preorders, in jeopardy of cancellation.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong